RE:RE:prospectus fillled1- Rookie mistake to determine patient eligibility in the study based on only 1 TG reading, not the medical history.
2- T2 might be better since conducted in smaller sites that hopefully take patient history more into account.
3- Overall I still do not think T2 will be a success based on FDA criteria (intent to treat population). It might be successful however with post-hoc analysis to exclude outliers.
4- A third phase 3 will likely be required, question is on how much time (12 weeks only of full 26?) and how much $$$ ?
5 - MANAGEMENT HAS TO GO. Yesterday's call was a disaster and only showed how incompetent and not in control they are (remember that part where Pierre and Jan were contradicting themselves when trying to say T1 and T2 were designed the same way but would have different results).
6 - BOARD HAS TO GO - Board has tolerated management actions for way too long, kept shareholders in the dark for 6 months with nothing positive or material coming out of it. Time for Mr Carter & friends to go too.
PS - Brian Grolch - When are they going to fire that guy??? Why keep paying a commercialization guy when you are only getting further away from market?